Risperdal Is First Drug To Receive Approval For Pediatric Schizophrenia
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s Risperdal paves the way for atypical antipsychotics in pediatric schizophrenia and bipolar I disorder market.